These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 31542847)
1. Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II). Hattori N; Nakayama G; Uehara K; Aiba T; Ishigure K; Sakamoto E; Tojima Y; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Nagino M; Kodera Y Int J Clin Oncol; 2020 Jan; 25(1):118-125. PubMed ID: 31542847 [TBL] [Abstract][Full Text] [Related]
2. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204. Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352 [TBL] [Abstract][Full Text] [Related]
3. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174 [TBL] [Abstract][Full Text] [Related]
4. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study. Seddik Y; Brahmi SA; Afqir S Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979 [TBL] [Abstract][Full Text] [Related]
5. Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer. Nishimura J; Hasegawa J; Kato T; Yoshioka S; Noura S; Kagawa Y; Yasui M; Ikenaga M; Murata K; Hata T; Matsuda C; Mizushima T; Yamamoto H; Doki Y; Mori M; Cancer Chemother Pharmacol; 2018 Oct; 82(4):707-716. PubMed ID: 30078098 [TBL] [Abstract][Full Text] [Related]
6. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J; Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374 [TBL] [Abstract][Full Text] [Related]
7. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133 [TBL] [Abstract][Full Text] [Related]
8. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study). Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885 [TBL] [Abstract][Full Text] [Related]
9. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study). Nakayama G; Takano N; Taniguchi H; Ishigure K; Yokoyama H; Teramoto H; Hashimoto R; Sakai M; Ishiyama A; Kinoshita T; Hayashi N; Nakamura M; Hattori N; Sato Y; Umeda S; Uehara K; Aiba T; Sonohara F; Hayashi M; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Murotani K; Ando M; Ando Y; Muro K; Kodera Y Eur J Cancer; 2021 Feb; 144():61-71. PubMed ID: 33340853 [TBL] [Abstract][Full Text] [Related]
10. Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases. Satake H; Hashida H; Tanioka H; Miyake Y; Yoshioka S; Watanabe T; Matsuura M; Kyogoku T; Inukai M; Kotake T; Okita Y; Matsumoto T; Yasui H; Kotaka M; Kato T; Kaihara S; Tsuji A Oncologist; 2021 Jul; 26(7):e1125-e1132. PubMed ID: 33977607 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial. Lin ZY; Zhang P; Chi P; Xiao Y; Xu XM; Zhang AM; Qiu XF; Wu JX; Yuan Y; Wang ZN; Qu XJ; Li X; Nie X; Yang M; Cai KL; Zhang WK; Huang Y; Sun Z; Hou ZG; Ma C; Cheng FZ; Tao KX; Zhang T Ann Oncol; 2024 Oct; 35(10):882-891. PubMed ID: 38964714 [TBL] [Abstract][Full Text] [Related]
12. Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. Schmoll HJ; Stein A; Van Cutsem E; Price T; Hofheinz RD; Nordlinger B; Daisne JF; Janssens J; Brenner B; Reinel H; Hollerbach S; Caca K; Fauth F; Hannig CV; Zalcberg J; Tebbutt N; Mauer ME; Marreaud S; Lutz MP; Haustermans K J Clin Oncol; 2021 Jan; 39(1):17-29. PubMed ID: 33001764 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study. Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042 [TBL] [Abstract][Full Text] [Related]
14. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy. Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study. Osawa H; Handa N; Minakata K Oncol Res; 2014; 22(5-6):325-31. PubMed ID: 26629945 [TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358 [TBL] [Abstract][Full Text] [Related]
17. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study. Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662 [TBL] [Abstract][Full Text] [Related]
18. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors]. Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549 [No Abstract] [Full Text] [Related]
19. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R; J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994 [TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T; Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]